Notably, since methyl Bardoxolone, a potent Nrf2 activator, increases the incidence of cardiovascular events, including heart failure and death, the clinical phase III trial testing its efficacy in the treatment of chronic kidney disease associated with type 2 diabetes was terminated [195]. This evidence concerns the gene NFE2L2 and type 2 diabetes mellitus.